阿帕替尼联合替吉奥治疗晚期食管癌的临床疗效

摘要/Abstract

摘要：

目的探究阿帕替尼联合替吉奥胶囊治疗晚期复发转移食管癌患者的疗效。方法选择2017年1月至2019年1月于山东省泰安市肿瘤防治院就诊的140例晚期食管癌患者作为研究对象,采用随机数表法将患者随机分为观察组(72例)和对照组(68例),观察组给予阿帕替尼联合替吉奥化疗,对照组仅给予替吉奥化疗,观察两组患者近远期疗效及不良反应。结果观察组客观缓解率为38.9%(28/72),明显优于对照组的22.1%(15/68),差异有统计学意义(χ²=4.655,P=0.031);观察组疾病控制率为88.9%(64/72),明显优于对照组的61.8%(42/68),差异有统计学意义(χ²=13.993,P<0.001)。观察组和对照组中位无进展生存期分别为5.9个月、2.7个月,中位总生存期分别为14.8个月、7.9个月,两组比较差异均有统计学意义(χ²=5.477,P=0.026;χ²=6.083,P=0.014)。两组患者不良反应均较轻,为1~2级,主要有乏力、白细胞减少、手足综合征、高血压、蛋白尿,观察组发生率分别为59.7%(43/72)、50.0%(36/72)、8.3%(6/72)、12.5%(9/72)、9.7%(7/72),对照组发生率分别为51.5%(35/68)、57.4%(39/68)、17.6%(12/68)、4.4%(3/68)、4.4%(3/68),两组比较差异均无统计学意义(χ²=0.965,P=0.326;χ²=0.760,P=0.383;χ²=2.708,P=0.100;χ²=2.919,P=0.088;χ²=0.794,P=0.373)。结论阿帕替尼联合替吉奥对复发转移食管癌治疗疗效较好,安全性及耐受性可。

关键词:食管肿瘤,治疗结果,阿帕替尼,替吉奥

Abstract:

ObjectiveTo explore the efficacy of apatinib combined with S-1 capsule in the treatment of patients with advanced recurrent and metastatic esophageal cancer.MethodsA total of 140 patients with advanced esophageal cancer were selected as test subjects from January 2017 to January 2019 in Shandong Tai'an Cancer Prophylaction-Therapeutic Hospital. These patients were randomly divided into observation group (72 cases) and control group (68 cases) using random number table method. The patients in the observation group were treated with oral apatinib combined with S-1 chemotherapy, and the patients in the control group was only given S-1 chemotherapy. The short-term and long-term efficacy and adverse reactions of the two groups were observed.ResultsThe objective remission rates of the observation group was 38.9% (28/72), higher than that in the control group (22.1%, 15/68), with a statistically significant difference (χ²=4.655,P=0.031). The disease control rate of the observation group was 88.9% (64/72), higher than that in the control group (61.8%, 42/68), and there was a significant difference between the two groups (χ²=13.993,P<0.001). The median progression-free survival of the observation group and the control group was 5.9 months and 2.7 months respectively, the median overall survival was 14.8 months and 7.9 months respectively, and there were significant differences between the two groups (χ²=5.477,P=0.026;χ²=6.083,P=0.014). The adverse reactions of the two groups were mild, grade 1-2, mainly including fatigue, leukopenia, hand-foot syndrome, hypertension and proteinuria, with incidences of 59.7% (43/72), 50.0% (36/72), 8.3% (6/72), 12.5% (9/72), 9.7% (7/72) in the observation group, and 51.5% (35/68), 57.4% (39/68), 17.6% (12/68), 4.4% (3/68), 4.4% (3/68) in the control group, there were no significant differences between the two groups (χ²=0.965,P=0.326;χ²=0.760,P=0.383;χ²=2.708,P=0.100;χ²=2.919,P=0.088;χ²=0.794,P=0.373).ConclusionApatinib combined with S-1 is effective, safe and tolerable in the treatment of recurrent and metastatic esophageal cancer.

Key words:Esophageal neoplasms,Treatment outcome,Apatinib,S-1

张雪伟, 苏培英, 彭雷, 卢鑫, 袁磊, 高玉娟. 阿帕替尼联合替吉奥治疗晚期食管癌的临床疗效[J]. 国际肿瘤学杂志, 2021, 48(1): 30-34.

Zhang Xuewei, Su Peiying, Peng Lei, Lu Xin, Yuan Lei, Gao Yujuan. Clinical efficacy of apatinib combined with S-1 in the treatment of advanced esophageal cancer[J]. Journal of International Oncology, 2021, 48(1): 30-34.

图/表3

组别	CR	PR	SD	PD	客观缓解	疾病控制
观察组(n=72)	0(0)	28(38.9)	36(50.0)	8(11.1)	28(38.9)	64(88.9)
对照组(n=68)	0(0)	15(22.1)	27(39.7)	26(38.2)	15(22.1)	42(61.8)
χ²值					4.655	13.993
P值					0.031	<0.001

表1

图1

组别	乏力	白细胞减少	手足综合征	高血压	蛋白尿
观察组(n=72)	43(59.7)	36(50.0)	6(8.3)	9(12.5)	7(9.7)
对照组(n=68)	35(51.5)	39(57.4)	12(17.6)	3(4.4)	3(4.4)
χ²值	0.965	0.760	2.708	2.919	0.794
P值	0.326	0.383	0.100	0.088	0.373

表2

参考文献27

[1]	黄镜, 王玺, 李群, 等. 晚期食管鳞癌药物治疗进展[J]. 中国癌症防治杂志, 2017,9(5):345-349. DOI: 10.3969/J.ISSN.1674-5671.2017.05.01.
[2]	王玺, 黄镜. 晚期食管鳞癌二线药物治疗的研究进展[J]. 癌症进展, 2015,13(4):357-360. DOI: 10.11877/j.issn.1672-1535.2015.13.04.02.
[3]	王峰, 樊青霞. 晚期食管癌内科治疗的现状与展望[J]. 中华肿瘤杂志, 2016,38(9):655-659. DOI: 10.3760/cma.j.issn.0253-3766.2016.09.004.
[4]	National Comprehensive Cancer Network, Inc. NCCN clinical practice guidelines in oncology: gastric cancer (Version 2. 2015)[EB/OL]. [2015-08-10]. http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf.
[5]	Akutsu Y, Kono T, Uesato M, et al. S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma[J]. Oncology, 2013,84(5):305-310. DOI: 10.1159/000348294. pmid:23595163
[6]	覃莉, 黄东宁, 黄健, 等. 伊立替康联合长春瑞滨二线治疗晚期食管癌的疗效分析[J]. 中国医学前沿杂志(电子版), 2015,7(6):147-149. DOI: 10.3969/j.issn.1674-7372.2015.06.029.
[7]	Hawkes E, Okines AF, Papamichael D, et al. Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer[J]. Eur J Cancer, 2011,47(8):1146-1151. DOI: 10.1016/j.ejca.2010.12.021. doi:10.1016/j.ejca.2010.12.021pmid:21269822
[8]	Petty RD, Dahle-Smith A, Stevenson DAJ, et al. Gefitinib and EGFR gene copy number aberrations in esophageal cancer[J]. J Clin Oncol, 2017,35(20):2279-2287. DOI: 10.1200/JCO.2016.70.3934. doi:10.1200/JCO.2016.70.3934pmid:28537764
[9]	Crosby T, Hurt CN, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial[J]. Lancet Oncol, 2013,14(7):627-637. DOI: 10.1016/S1470-2045(13)70136-0. pmid:23623280
[10]	Ilson DH, Moughan J, Suntharalingam M, et al. RTOG 0436: a phase Ⅲ trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery[J]. J Clin Oncol, 2014,32(suppl 15):4007.
[11]	Doi T, Piha-Paul SA, Jalal SI, et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma[J]. Clin Oncol, 2018,36(1):61-67. DOI: 10.1200/JCO.2017.74.9846.
[12]	Huang J, Xu B, Mo H, et al. Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma[J]. Clin Cancer Res, 2018,24(6):1296-1304. DOI: 10.1158/1078-0432.CCR-17-2439. doi:10.1158/1078-0432.CCR-17-2439pmid:29358502
[13]	Fontanella C, Ongaro E, Bolzonello S, et al. Clinical advances in the development of novel VEGFR2 inhibitors[J]. Ann Transl Med, 2014,2(12):123. DOI: 10.3978/j.issn.2305-5839.2014.08.14. doi:10.3978/j.issn.2305-5839.2014.08.14pmid:25568876
[14]	李晓, 郭青龙, 卢娜, 等. VEGFA/VEGFR作用于血管内皮细胞途径及其抑制剂研究进展[J]. 药物生物技术, 2016,23(3):274-278.
[15]	Zhang H. Apatinib for molecular targeted therapy in tumor[J]. Drug Des Devel Ther, 2015,9:6075-6081. DOI: 10.2147/DDDT.S97235. pmid:26622168
[16]	秦叔逵, 李进. 阿帕替尼治疗胃癌的临床应用专家共识[J]. 临床肿瘤学杂志, 2015,20(9):841-847.
[17]	张惠博, 宋启斌, 于金明, 等. 阿帕替尼治疗晚期胃癌的研究进展[J]. 肿瘤学杂志, 2019,25(6):573-576.
[18]	王学敏, 张维红, 杜伟娇, 等. 阿帕替尼用于一线治疗进展后晚期非鳞非小细胞肺癌的疗效和生存分析[J]. 中国肺癌杂志, 2017,20(11):761-768. DOI: 10.3779/j.issn.1009-3419.2017.11.07.
[19]	Lin Y, Wu Z, Zhang J, et al. Apatinib for metastatic breast cancer in non-clinical trial setting: satisfying efficacy regardless of previous anti-angiogenic treatment[J]. Tumor Biol, 2017,39(6):1010428317711033. DOI: 10.1177/1010428317711033.
[20]	秦叔逵, 白玉贤, 欧阳学农, 等. 阿帕替尼一线治疗晚期肝细胞癌的前瞻性、随机、开放、全国多中心Ⅱ期临床实验[J]. 临床肿瘤学杂志, 2017,22(12):1057-1065. DOI: 10.3969/j.issn.1009-0460.2017.12.001.
[21]	孙培培, 张龙, 张泰, 等. 单药阿帕替尼治疗二线及二线以上化疗失败的晚期大肠癌患者疗效分析[J]. 临床肿瘤学杂志, 2017,22(7):646-649. DOI: 10.3969/j.issn.1009-0460.2017.07.015.
[22]	Zhu B, Li J, Xie Q, et al. Efficacy and safety of apatinib monothe-rapy in advanced bone and soft tissue sarcoma: an observational study[J]. Cancer Biol Ther, 2018,19(3):198-204. DOI: 10.1080/15384047.2017.1416275. pmid:29261005
[23]	陈小飞, 徐克平, 孙晓阳, 等. 阿帕替尼治疗晚期放化疗失败的食管癌患者的期临床研究(Ahead-E301)[R]. OESO国际大会, 北京, 2019年.
[24]	Li J, Wang L. Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma[J]. Onco Targets Ther, 2017,10:3965-3969. DOI: 10.2147/OTT.S132756. doi:10.2147/OTT.S132756pmid:28860804
[25]	吴亚运, 程蒙蒙, 佘明金. 阿帕替尼联合替吉奥治疗晚期食管癌的临床疗效观察[J]. 临床医药文献电子杂志, 2018,5(67):50-52. DOI: 10.3877/j.issn.2095-8242.2018.67.026.
[26]	帖晓静, 申凤乾, 屈福莲, 等. 阿帕替尼联合替吉奥二线治疗复发转移食管癌疗效的初探[J]. 中国肿瘤生物治疗杂志, 2017,24(11):1315-1319. DOI: 10.3872/j.issn.1007-385X.2017.11.013.
[27]	刘颖, 王峰, 孟祥瑞, 等. 阿帕替尼联合替吉奥治疗一线化疗失败晚期食管鳞癌的临床效果[J]. 河南医学研究, 2019,28(2):207-209. DOI: 10.3969/j.issn.1004-437X.2019.02.006.